These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35052955)

  • 21. Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed
    Moon SG; Lim CH; Kang HJ; Choi A; Kim S; Oh JH
    J Clin Med; 2022 Jul; 11(15):. PubMed ID: 35956057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study.
    Romano M; Gravina AG; Nardone G; Federico A; Dallio M; Martorano M; Mucherino C; Romiti A; Avallone L; Granata L; Priadko K; Compare D; Tuccillo C; Romito MR; Sgambato D; Miranda A; Romano L; Loguercio C; Bazzoli F; Zagari RM
    Helicobacter; 2020 Aug; 25(4):e12694. PubMed ID: 32314519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minocycline/Amoxicillin-Based Bismuth Quadruple Therapy for
    You S; Tang X; Zhou J; Shen Y; Song X; Benghezal M; Marshall BJ; Tang H; Li H
    Microorganisms; 2024 Feb; 12(3):. PubMed ID: 38543480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
    Fiorini G; Saracino IM; Zullo A; Gatta L; Pavoni M; Vaira D
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 29094477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ilaprazole based bismuth-containing quadruple regimen for the first-line treatment of Helicobacter pylori infection: a multicenter, randomized, controlled clinical study].
    Gao W; Cheng H; Hu FL; Lü NH; Xie Y; Sheng JQ; Xu JM; Zhang LX; Zhang L; Chen Y; Zhang ZY; Zhang GX; Cui MH; Yang GB; Gao HJ; Yang L
    Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(30):2108-12. PubMed ID: 23158273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
    Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
    Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Quadruple regimens using domestically manufactured drugs in gastritis and duodenal ulcer patients for Helicobacter pylori eradication: a perspective, multicenter, randomized controlled trial].
    Gao W; Hu F; Cheng H; Wang H; Yang Y; Liang H; Zhang S; Meng F; Cui M; Wei H; Sheng J; An HJ; Jiang B; Chen Y; Li Y; Zuo X; Gong J; Zhao P; Dong L; Wang B; Jiang K; Zhang G; Li J; Zhao Y; Gao H; Yang L
    Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(4):260-4. PubMed ID: 26879784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
    Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC
    Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori.
    Nyssen OP; McNicholl AG; Gisbert JP
    Helicobacter; 2019 Apr; 24(2):e12570. PubMed ID: 30767339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
    Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
    Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
    Zullo A; De Francesco V; Bellesia A; Vassallo R; D'Angelo A; Scaccianoce G; Sacco R; Bresci G; Eramo A; Tanzilli A; Ridola L; Alvaro D; Londoni C; Brambilla G; Manta R; Di Ciaula A; Portincasa P
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ultimate eradication rate of Helicobacter pylori after first, second, or third-line therapy in Korea.
    Yoon K; Kim N; Nam RH; Suh JH; Lee S; Kim JM; Lee JY; Kwon YH; Choi YJ; Yoon H; Shin CM; Park YS; Lee DH
    J Gastroenterol Hepatol; 2015 Mar; 30(3):490-5. PubMed ID: 25363555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of second-line regimens for
    Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
    BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
    Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
    Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
    Nyssen OP; Perez-Aisa A; Castro-Fernandez M; Pellicano R; Huguet JM; Rodrigo L; Ortuñ J; O ; Gomez-Rodriguez BJ; Pinto RM; Areia M; Perona M; Nuñez O; Romano M; Gravina AG; Pozzati L; Fernandez-Bermejo M; Venerito M; Malfertheiner P; Fernanadez-Salazar L; Gasbarrini A; Vaira D; Puig I; Megraud F; O'Morain C; Gisbert JP;
    United European Gastroenterol J; 2021 Feb; 9(1):38-46. PubMed ID: 33176617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
    Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
    Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.
    Lee ST; Lee DH; Lim JH; Kim N; Park YS; Shin CM; Jo HJ; Song IS
    Gut Liver; 2015 Jul; 9(4):478-85. PubMed ID: 25071068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.